Wall Street expects a year-over-year increase in earnings on higher revenues when United Therapeutics (UTHR) reports results for the quarter ended March 2025. While this widely-known consensus outlook ...

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

Liquidia faced significant legal challenges from United Therapeutics, delaying the market entry of its PAH drug Yutrepia until after Tyvaso's patent expiry in 2025. Despite tentative FDA approval ...

Get the next trade alert free. Beam Therapeutics Inc. BEAM on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD ...

Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR). Over the next few years, therapeutic companies, which develop a wide variety of treatments for ...

Business information management and process optimisation specialist Unisphere Solutions NZ has joined knowledge work automation specialist M-Files’ partner programme. Comprised of strategic alliances, ...

Presented by Andrew Stine, United Therapeutics. Poster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 447 – Clinical Correlations with Cardiac Power Output-to-Mass and Left ...